News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
Presentation ACC 2018 MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery Presenter: Philip Devereaux March 12, 2018
News Conference News ACC 2018 Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis Todd Neale March 12, 2018
News Conference News ACC 2018 MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery Todd Neale March 11, 2018
News Conference News ACC 2018 ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More Shelley Wood March 11, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest Yael L. Maxwell March 20, 2017
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2016 Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding Todd Neale April 06, 2016